AAN 2023 Presentation Details: Title: Therapeutic Potential of Fosgonimeton, a Small-Molecule Positive Modulator of the Neurotrophic HGF/MET Pathway, in Neurodegenerative Conditions Format: Oral (abstract #3944, presentation #008) Session: S14: General Neurology: Emerging Therapies Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma Date/Time: Monday, April 24, at 2:24 p.m. EDT Title: Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating with Composite Clinical Score of Cognition and Function in Alzheimer's Disease Format: Oral (abstract #4214, presentation #008) Session: S26: Experimental Therapeutics in Dementia Presenter: Hans J. Moebius, M.D., Ph.D., Chief Medical Officer, Athira Pharma Date/Time: Tuesday, April 25, at 2:24 p.m. EDT Title: Small Molecule Positive Modulator of Hepatocyte Growth Factor (HGF)/MET, ATH-1105, Improves Function and Reduces Disease Biomarkers in a TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis Format: Poster (abstract #3277) Session: P8: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1 Presenter: Jewel Johnston, Ph.D., Director, In Vivo Pharmacology, Athira Pharma Date/Date: Tuesday, April 25, from 11:45 a.m. - 12:45 p.m. EDT All presentations will be available on the Scientific Publications & Presentations page of the company's website at www.athira.com. About Athira Pharma, Inc. Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action.